Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gloo Holdings Inc Ordinary | Patrick P. Gelsinger | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 3.34 per share. | 11 Sep 2026 | 50,000 | 365,499 | - | 3.3 | 166,875 | Class A Common Stock |
| Cinemark Holdings Inc | Valmir Fernandes | Pr - Cinemark International | Sale or transfer of securities back to the company at price $ 35.17 per share. | 11 Sep 2026 | 20,000 | 106,386 (0%) | 0% | 35.2 | 703,400 | Common Stock |
| Miami Intl Holdings Inc | Shelly Brown | EVP, Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.54 per share. | 11 Sep 2026 | 16,283 | 337,707 | - | 42.5 | 692,679 | Common Stock |
| Magnite Inc | Katie Evans | See Remarks | Sale of securities on an exchange or to another person at price $ 24.00 per share. | 11 Sep 2026 | 13,997 | 441,800 (0%) | 0% | 24 | 335,928 | Common Stock |
| Viavi Soln Inc | Paul McNab | EVP, Chief Mktg & Stgy Officer | Sale of securities on an exchange or to another person at price $ 38.96 per share. | 11 Sep 2026 | 7,509 | 29,162 (0%) | 0% | 39.0 | 292,551 | Common Stock |
| Viavi Soln Inc | Paul McNab | EVP, Chief Mktg & Stgy Officer | Sale of securities on an exchange or to another person at price $ 38.98 per share. | 11 Sep 2026 | 3,523 | 25,639 (0%) | 0% | 39.0 | 137,327 | Common Stock |
| Bank First Corp | Peter J. Van Sistine | Director | Sale of securities on an exchange or to another person at price $ 155.57 per share. | 11 Sep 2026 | 1,848 | 7,640 (0%) | 0% | 155.6 | 287,493 | Common Stock |
| Carter Bankshares Inc | Catharine L. Midkiff | Director | Sale of securities on an exchange or to another person at price $ 31.25 per share. | 11 Sep 2026 | 1,000 | 16,856 | - | 31.3 | 31,250 | Common Stock |
| Southside Bancshares Inc | John Mitchell Craddock | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.01 per share. | 11 Sep 2026 | 415 | 4,378 (0%) | 0% | 32.0 | 13,284 | Common Stock |
| Beasley Broadcast Grp Inc (Class A) | Shaun Peter Greening | CAO | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 11 Sep 2026 | 378 | 0 (0%) | 0% | 15.8 | 5,965 | Class A Common Stock |
| Moog Inc (Class A) | Donald R. Fishback | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Sep 2026 | 45 | 6,581 (0%) | 0% | 0 | Class A Common | |
| Royal Gold Inc | Martin Raffield | SVP, Operations | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Sep 2026 | 40 | 11,023 (0%) | 0% | 0 | Common Stock | |
| Gamestop Corp (Class A) | Ryan Cohen | Director, President, CEO and Chairman | Purchase of securities on an exchange or from another person at price $ 20.38 per share. | 10 Sep 2026 | 1,000,000 | 39,347,842 (59%) | 1% | 20.4 | 20,375,900 | Class A Common Stock, $0.001 par value per share |
| OrthoPediatrics corp | David R. Pelizzon | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 21.01 per share. | 10 Sep 2026 | 302,369 | 6,201,764 (36%) | 1% | 21.0 | 6,352,773 | Common Stock |
| Uber | Dara Khosrowshahi | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 70.96 per share. | 10 Sep 2026 | 141,000 | 1,367,100 (0%) | 0% | 71.0 | 10,005,952 | Common Stock |
| Alphatec Holdings Inc | Patrick S. Miles | Director, CEO | Purchase of securities on an exchange or from another person at price $ 8.81 per share. | 10 Sep 2026 | 115,000 | 5,893,551 (9%) | 0% | 8.8 | 1,013,150 | Common Stock |
| Upstart Holdings Inc | Paul Gu | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 25.55 per share. | 10 Sep 2026 | 50,000 | 130,000 | - | 25.6 | 1,277,500 | Common Stock |
| Stardust Power Inc | Udaychandra Devasper | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.16 per share. | 10 Sep 2026 | 49,315 | 76,987 | - | 0.2 | 7,890 | Common Stock |
| Lyell Immunopharma Inc | Jarrad Mattieu Aguirre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 47,500 | 47,500 | - | - | Option (right to buy) | |
| Bumble Inc (Class A) | Whitney Wolfe Herd | Director, Chief Executive Officer, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.98 per share. | 10 Sep 2026 | 46,752 | 1,306,029 | - | 3.0 | 139,321 | Class A Common Stock |
| Magnite Inc | Aaron Saltz | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.41 per share. | 10 Sep 2026 | 40,000 | 224,389 (0%) | 0% | 23.4 | 936,400 | Common Stock |
| ARMOUR Residential REIT Inc | Daniel C. Staton | Director, Chairman of the Board | Sale of securities on an exchange or to another person at price $ 15.86 per share. | 10 Sep 2026 | 35,583 | 0 (0%) | 0% | 15.9 | 564,418 | Common Stock |
| Health Catalyst Inc | Benjamin Albert | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.67 per share. | 10 Sep 2026 | 35,244 | 1,388,406 (3%) | 0% | 1.7 | 59,023 | Common Stock |
| AFC Gamma Inc | Leonard M. Tannenbaum | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 3.46 per share. | 10 Sep 2026 | 35,000 | 6,884,299 | - | 3.5 | 121,100 | Common Stock |
| Imax Corp | Robert Darin Lister | Chief Legal Officer Sr Exec VP | Sale of securities on an exchange or to another person at price $ 51.58 per share. | 10 Sep 2026 | 22,500 | 182,375 (0%) | 0% | 51.6 | 1,160,577 | common shares |
| Crawford & Co. (Class A) | Andrew John Bart | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2026 | 18,005 | 0 | - | - | Employee Stock Option (right to buy) | |
| Crawford & Co. (Class A) | Andrew John Bart | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.60 per share. | 10 Sep 2026 | 18,005 | 109,412 (0%) | 0% | 8.6 | 154,843 | Class A Common Stock |
| Celsius Holdings Inc | John Fieldly | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 27.44 per share. | 10 Sep 2026 | 18,000 | 956,063 (1%) | 0% | 27.4 | 493,843 | Common Stock, $0.001 par value per share |
| Crawford & Co. (Class A) | Andrew John Bart | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.22 per share. | 10 Sep 2026 | 17,959 | 104,354 (0%) | 0% | 9.2 | 165,582 | Class A Common Stock |
| Crawford & Co. (Class A) | Andrew John Bart | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2026 | 17,959 | 0 | - | - | Employee Stock Option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Sale of securities on an exchange or to another person at price $ 67.46 per share. | 10 Sep 2026 | 14,000 | 94,600 (0%) | 0% | 67.5 | 944,488 | Common Stock |
| CarPartscom Inc | David Meniane | CEO | Purchase of securities on an exchange or from another person at price $ 10.06 per share. | 10 Sep 2026 | 13,250 | 312,664 (0%) | 0% | 10.1 | 133,295 | Common Stock |
| CarPartscom Inc | Michael Huffaker | COO | Purchase of securities on an exchange or from another person at price $ 10.06 per share. | 10 Sep 2026 | 13,250 | 152,810 (0%) | 0% | 10.1 | 133,295 | Common Stock |
| Crawford & Co. (Class A) | Andrew John Bart | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.79 per share. | 10 Sep 2026 | 12,947 | 91,407 (0%) | 0% | 12.8 | 165,592 | Class A Common Stock |
| Crawford & Co. (Class A) | Andrew John Bart | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.47 per share. | 10 Sep 2026 | 12,418 | 96,994 (0%) | 0% | 12.5 | 154,852 | Class A Common Stock |
| Dorian LPG Ltd | Theodore B. Young | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 54.50 per share. | 10 Sep 2026 | 11,919 | 107,794 (0%) | 0% | 54.5 | 649,586 | Common Shares, $0.01 par value per share |
| Par Pacific Holdings Inc | Timothy Clossey | Director | Sale of securities on an exchange or to another person at price $ 84.00 per share. | 10 Sep 2026 | 10,970 | 51,526 (0%) | 0% | 84 | 921,480 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 10 Sep 2026 | 10,185 | 50,085 | - | 8.0 | 81,887 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.62 per share. | 10 Sep 2026 | 10,185 | 39,900 | - | 17.6 | 179,457 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2026 | 10,185 | 105,815 | - | - | Stock Option (Right to Buy) | |
| Pitney Bowes Inc | Todd A. Everett | EVP and President of SendTech | Sale of securities on an exchange or to another person at price $ 16.90 per share. | 10 Sep 2026 | 10,000 | 86,048 (0%) | 0% | 16.9 | 168,950 | Common Stock |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.44 per share. | 10 Sep 2026 | 10,000 | 101,500 (0%) | 0% | 17.4 | 174,400 | Common Stock |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2026 | 10,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2026 | 10,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.52 per share. | 10 Sep 2026 | 10,000 | 111,500 (0%) | 0% | 26.5 | 265,200 | Common Stock |
| Wealthfront Corp | Kenneth A. Goldman | Director | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 10 Sep 2026 | 10,000 | 49,655 | - | 10 | 100,000 | Common Stock |
| Sera Prognostics Inc (Class A) | Zhenya Lindgardt | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 10 Sep 2026 | 7,022 | 837,848 | - | 2 | 14,044 | Class A Common Stock |
| Kennametal Inc | Sanjay Chowbey | President and CEO | Purchase of securities on an exchange or from another person at price $ 29.10 per share. | 10 Sep 2026 | 7,000 | 246,839 (0%) | 0% | 29.1 | 203,700 | Common Stock |
| Angel Oak Mortgage REIT Inc | Wesley D. Minami | Director | Purchase of securities on an exchange or from another person at price $ 8.10 per share. | 10 Sep 2026 | 6,800 | 87,118 | - | 8.1 | 55,080 | Common Stock |
| MarketAxess Holdings Inc | William F. Cruger | Director | Sale of securities on an exchange or to another person at price $ 163.20 per share. | 10 Sep 2026 | 6,164 | 4,033 (0%) | 0% | 163.2 | 1,005,965 | Common Stock, par value $0.003 per share |
| eHealth Inc | John J. Dolan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 10 Sep 2026 | 5,859 | 337,416 (1%) | 0% | 0.9 | 5,390 | Common Stock |
| IRIDEX Corp | Romeo R. Dizon | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.68 per share. | 10 Sep 2026 | 5,100 | 175,052 (1%) | 0% | 0.7 | 3,468 | Common Stock |
| Gamestop Corp (Class A) | Alain Attal | Director | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 10 Sep 2026 | 5,000 | 601,464 (0%) | 0% | 20 | 100,000 | Class A Common Stock |
| Dorian LPG Ltd | Alexander C. Hadjipateras | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 54.13 per share. | 10 Sep 2026 | 5,000 | 95,836 (0%) | 0% | 54.1 | 270,650 | Common Shares, $0.01 par value per share |
| Anixa Biosciences Inc | Amit Kumar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.76 per share. | 10 Sep 2026 | 5,000 | 662,000 (3%) | 0% | 2.8 | 13,800 | Common Stock |
| Magnite Inc | Paul Caine | Director | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 10 Sep 2026 | 5,000 | 144,901 (0%) | 0% | 23.5 | 117,650 | Common Stock |
| eHealth Inc | Michelle M. Barbeau | Chief Revenue Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 10 Sep 2026 | 4,312 | 370,148 (1%) | 0% | 0.9 | 3,967 | Common Stock |
| Applied Optoelectronics Inc | Stefan J. Murry | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 105.33 per share. | 10 Sep 2026 | 4,000 | 367,168 (1%) | 0% | 105.3 | 421,320 | Common Stock, $.001 par value |
| Realty Income - REIT | Gregory T. McLaughlin | Director | Sale of securities on an exchange or to another person at price $ 60.15 per share. | 10 Sep 2026 | 3,475 | 34,732 (0%) | 0% | 60.2 | 209,022 | Common Stock |
| WSFS Fin Corp | Michael J. Donahue | Director | Sale of securities on an exchange or to another person at price $ 79.46 per share. | 10 Sep 2026 | 3,247 | 11,495 (0%) | 0% | 79.5 | 258,007 | Common Stock |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Sale of securities on an exchange or to another person at price $ 68.09 per share. | 10 Sep 2026 | 3,100 | 91,500 (0%) | 0% | 68.1 | 211,073 | Common Stock |
| JPMC | Robin Leopold | Head of Human Resources | Sale of securities on an exchange or to another person at price $ 352.81 per share. | 10 Sep 2026 | 2,500 | 71,047 (0%) | 0% | 352.8 | 882,027 | Common Stock |
| Anterix Inc | Leslie B. Daniels | Director | Sale of securities on an exchange or to another person at price $ 83.83 per share. | 10 Sep 2026 | 2,500 | 43,477 (0%) | 0% | 83.8 | 209,575 | Common Stock |
| Sera Prognostics Inc (Class A) | Benjamin G. Jackson | General Counsel | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 10 Sep 2026 | 2,190 | 159,566 | - | 2 | 4,380 | Class A Common Stock |
| Velocity Fin Inc | Mark R. Szczepaniak | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 10 Sep 2026 | 2,000 | 64,400 (0%) | 0% | 18.0 | 36,060 | Common Stock |
| Sera Prognostics Inc (Class A) | Lee Dyaarl Anderson | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 10 Sep 2026 | 1,800 | 76,198 | - | 2 | 3,600 | Class A Common Stock |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Sale of securities on an exchange or to another person at price $ 65.39 per share. | 10 Sep 2026 | 1,700 | 109,800 (0%) | 0% | 65.4 | 111,166 | Common Stock |
| Banner Corp | Karen Harrison | Executive VP, Banner Bank | Sale or transfer of securities back to the company at price $ 70.27 per share. | 10 Sep 2026 | 1,314 | 12,324 (0%) | 0% | 70.3 | 92,336 | Common Stock, $0.01 par value per share |
| PHINIA Inc | Matthew Logar | SVP and CIO | Sale of securities on an exchange or to another person at price $ 66.33 per share. | 10 Sep 2026 | 1,257 | 15,576 | - | 66.3 | 83,372 | Common Stock |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Sale of securities on an exchange or to another person at price $ 66.15 per share. | 10 Sep 2026 | 1,200 | 108,600 (0%) | 0% | 66.2 | 79,380 | Common Stock |
| Houlihan Lokey Inc (Class A) | Christopher M. Crain | GENERAL COUNSEL | 10 Sep 2026 | 1,000 | 0 | - | - | CLASS B COMMON STOCK | ||
| Houlihan Lokey Inc (Class A) | Christopher M. Crain | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 140.15 per share. | 10 Sep 2026 | 1,000 | 0 (0%) | 0% | 140.2 | 140,150 | CLASS A COMMON STOCK |
| Houlihan Lokey Inc (Class A) | Christopher M. Crain | GENERAL COUNSEL | 10 Sep 2026 | 1,000 | 1,000 (0%) | 0% | 0 | CLASS A COMMON STOCK | ||
| Lucky Strike Entertainment Corp (Class A) | Robert J. Bass | Director | Purchase of securities on an exchange or from another person at price $ 5.45 per share. | 10 Sep 2026 | 600 | 51,848 | - | 5.4 | 3,268 | Class A Common Stock |
| RGC Resources Inc | Paul W. Nester | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 21.30 per share. | 10 Sep 2026 | 500 | 134,212 (1%) | 0% | 21.3 | 10,650 | Common Stock |
| StoneX Grp Inc | Charles M. Lyon | President | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Sep 2026 | 500 | 324,242 (1%) | 0% | 0 | Common Stock | |
| Pinnacle Financial Partners | Gregory G. Montana | Director | Purchase of securities on an exchange or from another person at price $ 98.61 per share. | 10 Sep 2026 | 500 | 4,959 (0%) | 0% | 98.6 | 49,305 | Common Stock |
| Lyell Immunopharma Inc | David R. Shook | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.70 per share. | 10 Sep 2026 | 500 | 20,423 | - | 12.7 | 6,350 | Common Stock |
| Sera Prognostics Inc (Class A) | Tiffany Eul Davis Inglis | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 10 Sep 2026 | 486 | 91,589 | - | 2 | 972 | Class A Common Stock |
| Diageo PLC (ADR) | John Alexander Manzoni | Non-Executive Director,Chairman | Purchase of securities on an exchange or from another person at price $ 15.85 per share. | 10 Sep 2026 | 414 | 10,349 (0%) | 0% | 15.9 | 6,562 | Ords |
| Weyco Grp Inc | Dustin Combs | VP, PRESIDENT - BOGS & RAFTERS | Sale of securities on an exchange or to another person at price $ 44.17 per share. | 10 Sep 2026 | 290 | 4,094 (0%) | 0% | 44.2 | 12,809 | Common Stock |
| Verizon Communincations | Rodriguez Alfonso Villanueva | EVP and Group CEO-VZ Consumer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 252 | 7,339 | - | - | Phantom Stock (unitized) | |
| Carlisle Companies Inc | Sheryl D. Palmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 246 | 246 | - | - | Deferred Stock Units | |
| Cass Information Systems Inc | Joseph D. Rupp | Director | Grant, award, or other acquisition of securities at price $ 55.08 per share. | 10 Sep 2026 | 236 | 24,217 (0%) | 0% | 55.1 | 12,999 | Common Stock |
| Cass Information Systems Inc | Franklin D. Wicks | Director | Grant, award, or other acquisition of securities at price $ 55.08 per share. | 10 Sep 2026 | 236 | 34,519 (0%) | 0% | 55.1 | 12,999 | Common Stock |
| Cass Information Systems Inc | Randall L. Schilling | Director | Grant, award, or other acquisition of securities at price $ 55.08 per share. | 10 Sep 2026 | 236 | 33,886 (0%) | 0% | 55.1 | 12,999 | Common Stock |
| Carlisle Companies Inc | James D. Frias | Director | Other type of transaction at price $ 329.74 per share. | 10 Sep 2026 | 197 | 5,723 (0%) | 0% | 329.7 | 64,959 | Common Stock |
| Carlisle Companies Inc | Corrine D. Ricard | Director | Other type of transaction at price $ 329.74 per share. | 10 Sep 2026 | 197 | 6,015 (0%) | 0% | 329.7 | 64,959 | Common Stock |
| Verizon Communincations | Daniel H. Schulman | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 186 | 9,408 | - | - | Phantom Stock (unitized) | |
| Diageo PLC (ADR) | Manik H. Jhangiani | Executive Director,Chief Financial Officer | 10 Sep 2026 | 183 | 127,771 (0%) | 0% | 0 | Ords | ||
| Diageo PLC (ADR) | Dave J. Lewis | Executive Director,Chief Executive Officer | 10 Sep 2026 | 183 | 183 (0%) | 0% | 0 | Ords | ||
| Verizon Communincations | Anthony T. Skiadas | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 121 | 147,111 | - | - | Phantom Stock (unitized) | |
| Verizon Communincations | Kyle Malady | EVP and Group CEO-VZ Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 121 | 424,383 | - | - | Phantom Stock (unitized) | |
| MarketAxess Holdings Inc | Scott Pintoff | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 163.32 per share. | 10 Sep 2026 | 100 | 11,486 (0%) | 0% | 163.3 | 16,332 | Common Stock, par value $0.003 per share |
| Verizon Communincations | Vandana Venkatesh | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 89 | 58,019 | - | - | Phantom Stock (unitized) | |
| Verizon Communincations | Joseph J. Russo | EVP&Pres-Global Networks&Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 77 | 84,951 | - | - | Phantom Stock (unitized) | |
| Norwood Fin Corp | Andrew A. Forte | Director | Grant, award, or other acquisition of securities at price $ 34.48 per share. | 10 Sep 2026 | 48 | 12,376 (0%) | 0% | 34.5 | 1,655 | Common Stock |
| Verizon Communincations | Mary-Lee Stillwell | SVP and Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2026 | 41 | 17,143 | - | - | Phantom Stock (unitized) | |
| Norwood Fin Corp | Kevin M. Lamont | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 136,127 (2%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Ralph A. Matergia | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 26,685 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Kenneth A. Phillips | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 15,972 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Meg L. Hungerford | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 6,410 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Jeffrey S. Gifford | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 26,849 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Alexandra K. Nolan | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 2,973 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Joseph W. Carroll | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 41,906 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Spencer J. Andress | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 8,492 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Ronald R. Schmalzle | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 8,957 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | James Shook | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 12,665 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Norwood Fin Corp | Marissa S. Nacinovich | Director | Grant, award, or other acquisition of securities at price $ 34.46 per share. | 10 Sep 2026 | 39 | 651 (0%) | 0% | 34.5 | 1,344 | Common Stock |
| Union Pacific | Jennifer L. Hamann | EVP & CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 301.29 per share. | 10 Sep 2026 | 7 | 114,682 (0%) | 0% | 301.3 | 2,109 | Common Stock |
| Union Pacific | Rahul Jalali | EVP & CHIEF INFORMATION OFFICE | Grant, award, or other acquisition of securities at price $ 292.80 per share. | 10 Sep 2026 | 5 | 33,136 (0%) | 0% | 292.8 | 1,464 | Common Stock |
| Union Pacific | Carrie J. Powers | VP & CONTROLLER | Grant, award, or other acquisition of securities at price $ 316.00 per share. | 10 Sep 2026 | 5 | 8,146 (0%) | 0% | 316 | 1,580 | Common Stock |
| BP PLC (ADR) | Katherine Anne Thomson | Executive Director,Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.67 per share. | 10 Sep 2026 | 3 | 1,420,839 (0%) | 0% | 5.7 | 17 | Ords |
| Union Pacific | Kenyatta G. Rocker | EVP MARKETING & SALES | Grant, award, or other acquisition of securities at price $ 372.00 per share. | 10 Sep 2026 | 2 | 1,311 (0%) | 0% | 372 | 744 | Common Stock |
| Union Pacific | Christina B. Conlin | EVP CHIEF LEGAL OFFICER & CORP | Grant, award, or other acquisition of securities at price $ 317.50 per share. | 10 Sep 2026 | 2 | 16,013 (0%) | 0% | 317.5 | 635 | Common Stock |
| Barinthus Biotherapeutics PLC. (ADR) | William J. Enright | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 728,454 | 0 | - | - | Ordinary Shares | |
| Barinthus Biotherapeutics PLC. (ADR) | William J. Enright | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 600,000 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | William J. Enright | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 514,923 | 0 | - | - | Ordinary Shares | |
| Barinthus Biotherapeutics PLC. (ADR) | William J. Enright | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 443,981 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | William J. Enright | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 440,000 | 0 | - | - | Share Option (Right to Buy) | |
| Opus Genetics Inc | George Magrath | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.15 per share. | 09 Sep 2026 | 392,157 | 2,124,026 | - | 1.2 | 450,981 | Common Stock |
| Opus Genetics Inc | George Magrath | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2026 | 392,157 | 0 | - | - | Warrant (right to buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Leon Hooftman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 361,530 | 361,530 | - | - | Ordinary Shares | |
| Barinthus Biotherapeutics PLC. (ADR) | Leon Hooftman | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 361,530 | 0 | - | - | Ordinary Shares | |
| Barinthus Biotherapeutics PLC. (ADR) | William J. Enright | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 359,605 | 0 | - | - | Share Option (Right to Buy) | |
| Angel Studios Inc Ordinary | Steven I. Sarowitz | Director | Purchase of securities on an exchange or from another person at price $ 5.28 per share. | 09 Sep 2026 | 355,998 | 1,240,841 | - | 5.3 | 1,879,349 | Class A Common Stock, par value $0.0001 per share |
| Warner Bros. (Class A) | Amy Girdwood | Chief People & Culture Officer | Sale of securities on an exchange or to another person at price $ 27.98 per share. | 09 Sep 2026 | 262,285 | 539,374 (0%) | 0% | 28.0 | 7,338,734 | Series A Common Stock |
| Telos Corp | Gary Mark Bendza | EVP, CFO | Sale of securities on an exchange or to another person at price $ 4.55 per share. | 09 Sep 2026 | 200,000 | 537,008 | - | 4.6 | 910,000 | Common Stock |
| Barinthus Biotherapeutics PLC. (ADR) | Leon Hooftman | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 195,166 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | William J. Enright | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 176,130 | 0 | - | - | Share Option (Right to Buy) | |
| Rigetti Computing Inc | Subodh K. Kulkarni | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.96 per share. | 09 Sep 2026 | 150,000 | 260,411 | - | 1.0 | 144,570 | Common Stock |
| Rigetti Computing Inc | Subodh K. Kulkarni | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2026 | 150,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Century Therapeutics Inc | Joseph Truitt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 148,000 | 148,000 | - | - | Stock Option (right to buy) | |
| AdaptHealth Corp | Harriss T. Currie | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 141,372 | 141,372 (0%) | 0% | 0 | Common Stock | |
| Barinthus Biotherapeutics PLC. (ADR) | Leon Hooftman | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 140,000 | 0 | - | - | Share Option (Right to Buy) | |
| Angel Studios Inc Ordinary | Steven I. Sarowitz | Director | Purchase of securities on an exchange or from another person at price $ 4.95 per share. | 09 Sep 2026 | 132,639 | 884,843 | - | 5.0 | 657,054 | Class A Common Stock, par value $0.0001 per share |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.20 per share. | 09 Sep 2026 | 120,200 | 920,200 (6%) | 0% | 4.2 | 504,840 | Common Stock |
| Rigetti Computing Inc | Subodh K. Kulkarni | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.68 per share. | 09 Sep 2026 | 120,000 | 140,411 | - | 15.7 | 1,882,104 | Common Stock |
| Lululemon Athletica | Heidi O'Neill | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 105,295 | 105,295 | - | - | Stock Options (Right to Buy) | |
| Grace Therapeutics Inc | Prashant Kohli | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.14 per share. | 09 Sep 2026 | 100,000 | 121,357 (0%) | 0% | 2.1 | 214,000 | Common Stock |
| Scynexis Inc | Sanjay Subramanian | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.18 per share. | 09 Sep 2026 | 100,000 | 1,400,000 (9%) | 0% | 4.2 | 418,000 | Common Stock |
| Relmada Therapeutics Inc | Sergio Traversa | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.10 per share. | 09 Sep 2026 | 100,000 | 1,500,000 (10%) | 0% | 4.1 | 410,000 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.25 per share. | 09 Sep 2026 | 79,800 | 1,000,000 (6%) | 0% | 4.3 | 339,150 | Common Stock |
| Genpact Ltd | Sumita Pandit | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 76,713 | 76,713 (0%) | 0% | 0 | Common Shares | |
| Whitehawk Therapeutics Inc | Vijay K. Iyengar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 76,080 | 76,080 | - | - | Stock Option (right to buy) | |
| Opus Genetics Inc | George Magrath | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.97 per share. | 09 Sep 2026 | 75,541 | 2,048,485 | - | 6.0 | 450,980 | Common Stock |
| Complete Solaria Inc (Class A) | Adam Gishen | Director | Sale of securities on an exchange or to another person at price $ 0.31 per share. | 09 Sep 2026 | 70,000 | 140,655 | - | 0.3 | 21,700 | Common Stock |
| NextDecade Corp | Matthew Schatzman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.54 per share. | 09 Sep 2026 | 69,583 | 5,319,526 (4%) | 0% | 7.5 | 524,656 | Common Stock |
| Essential Properties Realty Trust Inc | Robert Max Jenkins | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 67,476 | 87,971 | - | - | OP Units | |
| Essential Properties Realty Trust Inc | Robert W. Salisbury | Executive VP, CFO and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 67,476 | 83,324 | - | - | OP Units | |
| Starbucks | Brian R. Niccol | Director, chairman and ceo | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.04 per share. | 09 Sep 2026 | 56,267 | 428,696 (0%) | 0% | 100.0 | 5,628,951 | Common Stock |
| Dorian LPG Ltd | Tim T. Hansen | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 53.12 per share. | 09 Sep 2026 | 50,000 | 107,675 (0%) | 0% | 53.1 | 2,655,890 | Common Shares, $0.01 par value per share |
| Korsana Biosciences Inc | Nimish Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 48,445 | 48,445 | - | - | Stock Option (Right to Buy) | |
| Korsana Biosciences Inc | Andrew Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 48,445 | 48,445 | - | - | Stock Option (Right to Buy) | |
| Korsana Biosciences Inc | Michelle Patricia Pernice | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 48,445 | 48,445 | - | - | Stock Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Robin Wright | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 48,256 | 0 | - | - | Ordinary Shares | |
| Innventure Inc | Gregory William Haskell | Former Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 09 Sep 2026 | 46,460 | 933,343 | - | 0 | Common Stock | |
| Invesco Ltd | Stephanie C. Butcher | Senior Managing Director | Sale of securities on an exchange or to another person at price $ 32.28 per share. | 09 Sep 2026 | 45,095 | 10,205 (0%) | 0% | 32.3 | 1,455,779 | Common Shares |
| Chime Fin Inc (Class A) | Ryan King | Director, Co-Founder | Sale of securities on an exchange or to another person at price $ 35.15 per share. | 09 Sep 2026 | 42,421 | 0 | - | 35.1 | 1,490,996 | Class A Common Stock |
| Lululemon Athletica | Heidi O'Neill | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 40,223 | 40,223 | - | - | Stock Options (Right to Buy) | |
| Beta Bionics Inc | Mark Hopman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.46 per share. | 09 Sep 2026 | 36,870 | 87,157 | - | 18.5 | 680,723 | Common Stock |
| Chime Fin Inc (Class A) | Ryan King | Director, Co-Founder | 09 Sep 2026 | 34,941 | 42,421 | - | 0 | Class A Common Stock | ||
| Chime Fin Inc (Class A) | Ryan King | Director, Co-Founder | 09 Sep 2026 | 34,941 | 11,810,900 | - | - | Class B Common Stock | ||
| Barinthus Biotherapeutics PLC. (ADR) | Karen A. Dawes | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 34,328 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Anne M. Phillips | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 34,328 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Robin Wright | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 34,328 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Alex Hammacher | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 34,328 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Pierre A. Morgon | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 34,328 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Joseph C.F. Scheeren | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 34,328 | 0 | - | - | Share Option (Right to Buy) | |
| Lucky Strike Entertainment Corp (Class A) | Thomas F. Shannon | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 5.86 per share. | 09 Sep 2026 | 30,000 | 3,144,000 | - | 5.9 | 175,800 | Class A Common Stock |
| Lam Research | Timothy M. Archer | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2026 | 30,000 | 31,400 | - | - | Employee Stock Option (Right to Buy) | |
| Lam Research | Timothy M. Archer | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.03 per share. | 09 Sep 2026 | 30,000 | 1,105,966 (0%) | 0% | 30.0 | 900,990 | Common Stock |
| Lam Research | Timothy M. Archer | President and CEO | Sale of securities on an exchange or to another person at price $ 319.26 per share. | 09 Sep 2026 | 30,000 | 1,075,966 (0%) | 0% | 319.3 | 9,577,800 | Common Stock |
| WisdomTree Inc | R. Jarrett | President and COO | Sale of securities on an exchange or to another person at price $ 24.56 per share. | 09 Sep 2026 | 30,000 | 1,080,245 (0%) | 0% | 24.6 | 736,800 | Common Stock |
| Elastic N.V | Ashutosh Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.78 per share. | 09 Sep 2026 | 29,227 | 599,525 (0%) | 0% | 87.8 | 2,565,546 | Ordinary Shares |
| Lululemon Athletica | Heidi O'Neill | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2026 | 28,079 | 28,079 | - | - | Restricted Stock Units | |
| Insmed Inc | David R. Brennan | Director | Sale of securities on an exchange or to another person at price $ 124.00 per share. | 09 Sep 2026 | 25,000 | 39,238 (0%) | 0% | 124 | 3,100,000 | Common Stock |
| Barinthus Biotherapeutics PLC. (ADR) | Joseph C.F. Scheeren | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 23,000 | 0 | - | - | Ordinary Shares | |
| Oxford Ind Inc | Thomas C. Chubb | Director, CEO and President | Other type of transaction at price $ 0.00 per share. | 09 Sep 2026 | 21,660 | 21,660 (0%) | 0% | 0 | Common Stock | |
| Oxford Ind Inc | Thomas C. Chubb | Director, CEO and President | Other type of transaction at price $ 0.00 per share. | 09 Sep 2026 | 21,660 | 30,200 (0%) | 0% | 0 | Common Stock | |
| Barinthus Biotherapeutics PLC. (ADR) | Robin Wright | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,394 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Pierre A. Morgon | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,394 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Karen A. Dawes | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,174 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Anne M. Phillips | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,174 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Robin Wright | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,174 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Alex Hammacher | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,174 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Pierre A. Morgon | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,174 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Joseph C.F. Scheeren | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 20,174 | 0 | - | - | Share Option (Right to Buy) | |
| BlackSky Tech Inc (Class A) | Brian E. O'Toole | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 09 Sep 2026 | 20,000 | 1,119,676 | - | 21.8 | 436,600 | Class A Common Stock |
| United States Lime & Minerals Inc | Antoine M. Doumet | Director | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 09 Sep 2026 | 20,000 | 90,000 (1%) | 0% | 110 | 2,200,000 | USLM Common Stock |
| Barinthus Biotherapeutics PLC. (ADR) | Karen A. Dawes | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,516 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Anne M. Phillips | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,516 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Robin Wright | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,516 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Alex Hammacher | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,516 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Pierre A. Morgon | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,516 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Joseph C.F. Scheeren | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,516 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Karen A. Dawes | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,197 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Anne M. Phillips | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,197 | 0 | - | - | Share Option (Right to Buy) | |
| Barinthus Biotherapeutics PLC. (ADR) | Robin Wright | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Sep 2026 | 19,197 | 0 | - | - | Share Option (Right to Buy) |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.